Commonwealth Bank of Australia boosted its stake in MEDNAX Inc (NYSE:MD) by 10.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,600 shares of the company’s stock after purchasing an additional 1,200 shares during the quarter. Commonwealth Bank of Australia’s holdings in MEDNAX were worth $415,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. Bremer Trust National Association purchased a new stake in MEDNAX in the fourth quarter valued at approximately $44,000. First Mercantile Trust Co. raised its stake in MEDNAX by 13.8% in the fourth quarter. First Mercantile Trust Co. now owns 2,275 shares of the company’s stock valued at $76,000 after purchasing an additional 275 shares in the last quarter. ETF Managers Group LLC raised its stake in MEDNAX by 18.8% in the fourth quarter. ETF Managers Group LLC now owns 2,404 shares of the company’s stock valued at $79,000 after purchasing an additional 381 shares in the last quarter. First Bank & Trust raised its stake in MEDNAX by 14.3% in the fourth quarter. First Bank & Trust now owns 2,808 shares of the company’s stock valued at $93,000 after purchasing an additional 351 shares in the last quarter. Finally, Ffcm LLC raised its stake in MEDNAX by 137.0% in the fourth quarter. Ffcm LLC now owns 3,155 shares of the company’s stock valued at $104,000 after purchasing an additional 1,824 shares in the last quarter. 93.75% of the stock is currently owned by institutional investors and hedge funds.

Shares of NYSE MD opened at $30.04 on Monday. The company has a current ratio of 1.31, a quick ratio of 1.31 and a debt-to-equity ratio of 0.64. MEDNAX Inc has a 52 week low of $29.34 and a 52 week high of $57.61. The firm has a market capitalization of $2.64 billion, a P/E ratio of 8.56, a PEG ratio of 1.05 and a beta of 0.61.

MEDNAX (NYSE:MD) last issued its earnings results on Thursday, February 7th. The company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.83 by $0.09. MEDNAX had a net margin of 7.37% and a return on equity of 10.35%. The company had revenue of $932.70 million for the quarter, compared to the consensus estimate of $910.08 million. During the same period in the previous year, the firm earned $0.87 earnings per share. The firm’s revenue for the quarter was up 2.4% on a year-over-year basis. On average, analysts anticipate that MEDNAX Inc will post 3.43 earnings per share for the current fiscal year.

In related news, insider John C. Pepia sold 2,500 shares of MEDNAX stock in a transaction on Tuesday, January 22nd. The shares were sold at an average price of $36.60, for a total value of $91,500.00. Following the transaction, the insider now directly owns 28,583 shares of the company’s stock, valued at $1,046,137.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Dominic J. Andreano sold 4,608 shares of MEDNAX stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $30.16, for a total transaction of $138,977.28. Following the completion of the transaction, the senior vice president now directly owns 64,461 shares in the company, valued at $1,944,143.76. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 30,279 shares of company stock worth $988,954. 2.70% of the stock is owned by insiders.

A number of equities research analysts recently weighed in on the stock. Credit Suisse Group lowered their target price on shares of MEDNAX from $44.00 to $42.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 13th. Mizuho set a $36.00 target price on shares of MEDNAX and gave the company a “hold” rating in a research note on Friday, February 8th. Zacks Investment Research downgraded shares of MEDNAX from a “hold” rating to a “sell” rating in a research note on Wednesday, February 6th. Citigroup raised shares of MEDNAX from a “neutral” rating to a “buy” rating and set a $34.88 target price on the stock in a research note on Monday, January 14th. They noted that the move was a valuation call. Finally, Deutsche Bank started coverage on shares of MEDNAX in a research note on Thursday, January 3rd. They set a “hold” rating and a $34.00 price target on the stock. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $41.39.

WARNING: This story was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://www.thecerbatgem.com/2019/03/18/mednax-inc-md-position-raised-by-commonwealth-bank-of-australia.html.

MEDNAX Profile

MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care services; and acute and chronic pain management services.

Featured Article: Hedge Funds – Risk or Reward?

Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MEDNAX Inc (NYSE:MD).

Institutional Ownership by Quarter for MEDNAX (NYSE:MD)

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.